Trial Profile
A phase I trial of MIN 301 for the treatment of Parkinson's disease
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 26 May 2015
Price :
$35
*
At a glance
- Drugs MIN 301 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- 26 May 2015 New trial record
- 26 Mar 2015 According to a company media release, Minerva Neurosciences plans to file an Investigational New Drug (IND) application in 2016 and initiate this study following its acceptance.